These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 17322470)

  • 1. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation.
    Yokoi M; Yamagishi S; Takeuchi M; Matsui T; Yoshida Y; Ohgami K; Amano-Okamoto T; Ohno S
    Br J Ophthalmol; 2007 Mar; 91(3):397-8. PubMed ID: 17322470
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells.
    Hirata C; Nakano K; Nakamura N; Kitagawa Y; Shigeta H; Hasegawa G; Ogata M; Ikeda T; Sawa H; Nakamura K; Ienaga K; Obayashi H; Kondo M
    Biochem Biophys Res Commun; 1997 Jul; 236(3):712-5. PubMed ID: 9245719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
    Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
    Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation.
    Spranger J; Hammes HP; Preissner KT; Schatz H; Pfeiffer AF
    Diabetologia; 2000 Nov; 43(11):1404-7. PubMed ID: 11126410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
    Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
    Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of proliferative diabetic retinopathy.
    Gündüz K; Bakri SJ
    Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Kezuka T; Takeuchi M; Goto H; Iwasaki T
    Retina; 2010 Feb; 30(2):339-44. PubMed ID: 20142713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous].
    Hashimoto H; Arai K; Chikuda M; Obara Y
    Nippon Ganka Gakkai Zasshi; 1998 Jul; 102(7):442-6. PubMed ID: 9720366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB
    Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines.
    Funatsu H; Yamashita H; Mimura T; Noma H; Nakamura S; Hori S
    Eye (Lond); 2007 Mar; 21(3):377-82. PubMed ID: 16410812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.
    Funatsu H; Yamashita H; Noma H; Mimura T; Sakata K; Hori S
    Br J Ophthalmol; 2004 Aug; 88(8):1064-8. PubMed ID: 15258026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological approach to diabetic retinopathy.
    De La Cruz JP; González-Correa JA; Guerrero A; de la Cuesta FS
    Diabetes Metab Res Rev; 2004; 20(2):91-113. PubMed ID: 15037985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy.
    Shinoda K; Ishida S; Kawashima S; Wakabayashi T; Uchita M; Matsuzaki T; Takayama M; Shinmura K; Yamada M
    Curr Eye Res; 2000 Aug; 21(2):655-61. PubMed ID: 11148602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
    Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ
    Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photocoagulation in advanced diabetic retinopathy, with special references to vitreous retraction.
    Tengroth B; Ostberg E
    Trans Ophthalmol Soc U K (1962); 1972; 92():845-7. PubMed ID: 4515564
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study.
    Fosmark DS; Bragadóttir R; Stene-Johansen I; Berg JP; Berg TJ; Lund T; Sandvik L; Hanssen KF
    Acta Ophthalmol Scand; 2007 Sep; 85(6):618-22. PubMed ID: 17488318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
    Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY
    Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.